Clinical Toxicology is the study of agents that cause toxic or adverse effects to the body. This sub-field usually deals with the side effects of drugs or chemicals given to a patient in order to treat other symptoms or diseases.
The implications of NIH BRAIN research stretch beyond traditional medical and research contexts. This LabRoots session will present recent developments at the intersection of neuroscience and...
What motivates patients to participate in clinical trials? Discussions most often revolve around potential study participants’ perception of therapeutic benefit. Misconceptions about th...
Developing new diagnostic and therapeutic tools for brain disorders is an ethical imperative and conducting human research with neural devices is a key step towards achieving that goal. Condu...
The NIH BRAIN Initiative aims to develop new tools and neurotechnologies to transform our understanding of brain function in health and disease. That knowledge is critical to enable novel the...
Humans have a remarkable ability to flexibly interact with the environment. A compelling demonstration of this cognitive flexibility is our ability to perform complex, yet previously un-pract...
Humans interact with their environment in countless ways and can switch seamlessly between activities. Even for seemingly simple tasks, a variety of sensory inputs and contextual cues are int...
The rapid formation of new memories and the recall of old memories to inform decisions is essential for human cognition, but the underlying neural mechanisms remain poorly understood. We util...
The human brain has a remarkable ability to store and retrieve information. Detailed memories can be formed after as little as one exposure, and those memories can be retained for decades. Im...
NIH representatives from the BRAIN Initiative will be presenting an overview of the NIH BRAIN Initiative and describing funding opportunity announcements (FOAs) supporting impacts in human ne...
Joshua Gordon, M.D., Ph.D., Director of the National Institute of Mental Health, will provide an overview of challenges and opportunities in mental health research. Dr. Gordon will present em...
Dramatic responses observed with targeted agents in the ‘right’ genomic context have fueled large scale sequencing efforts to identify ‘effective’ treatments for a giv...
Whether you are performing killing assays, immunophenotyping of TILs, characterizing the tumor microenvironment, or investigating immunogenicity, primary cells are essential for the discovery...
In today's presentation I will give an overview to developing NextGen ADCs. We will discuss everything from the beginning stages of development to the varying ADC combination therapies av...
In-vitro epithelial barrier models that are more representative of in-vivo tissues are urgently needed. Here we present extracellular matrix-supported intestinal tubules in a perfused microfl...
Cellular research is optimal when using physiologically-relevant cell phenotypes and genotypes of human origin. This assertion has accelerated the adoption of primary cells, stem cells, and i...
Small size, highly selective nature, flexible chemistry and ease of manufacturing make nucleic acid aptamers attractive for multiple applications in human diagnostics and drug discovery. &nbs...
NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events an...
Isolated hepatocytes or their enzymes comprise the basis of most in vitro DMPK and toxicity assays used to predict human hepatic outcomes. Because hepato-specific functions are typically lost...
Too frequently the investigator will provide “scientific” reasons to justify precluding analgesics from experimental procedures that may involve more than momentary pain, often wi...
Surgery is the first line of treatment for Stage III melanoma. Often adjuvant therapy is administered post-surgery, which can include weeks of radiation, chemotherapy, targeted drug therapy,...
Studies in drug development and on hematological and solid Tumors with a Thymidine Kinase 1 immunoassayThere are many tumor biomarkers but, they mostly reflect tumor mass or past growth,...
NanoMIPs, often called “plastic antibodies”, are made using a proprietary self-assembly process where the template molecule is incubated with monomers, each of which is free in so...
Advanced Cell Diagnostics’ RNAscope products and assay services are utilized widely for tissue-based gene expression analysis in early target validation, preclinical animal efficacy and...
The implications of NIH BRAIN research stretch beyond traditional medical and research contexts. This LabRoots session will present recent developments at the intersection of neuroscience and...
What motivates patients to participate in clinical trials? Discussions most often revolve around potential study participants’ perception of therapeutic benefit. Misconceptions about th...
Developing new diagnostic and therapeutic tools for brain disorders is an ethical imperative and conducting human research with neural devices is a key step towards achieving that goal. Condu...
The NIH BRAIN Initiative aims to develop new tools and neurotechnologies to transform our understanding of brain function in health and disease. That knowledge is critical to enable novel the...
Humans have a remarkable ability to flexibly interact with the environment. A compelling demonstration of this cognitive flexibility is our ability to perform complex, yet previously un-pract...
Humans interact with their environment in countless ways and can switch seamlessly between activities. Even for seemingly simple tasks, a variety of sensory inputs and contextual cues are int...
The rapid formation of new memories and the recall of old memories to inform decisions is essential for human cognition, but the underlying neural mechanisms remain poorly understood. We util...
The human brain has a remarkable ability to store and retrieve information. Detailed memories can be formed after as little as one exposure, and those memories can be retained for decades. Im...
NIH representatives from the BRAIN Initiative will be presenting an overview of the NIH BRAIN Initiative and describing funding opportunity announcements (FOAs) supporting impacts in human ne...
Joshua Gordon, M.D., Ph.D., Director of the National Institute of Mental Health, will provide an overview of challenges and opportunities in mental health research. Dr. Gordon will present em...
Dramatic responses observed with targeted agents in the ‘right’ genomic context have fueled large scale sequencing efforts to identify ‘effective’ treatments for a giv...
Whether you are performing killing assays, immunophenotyping of TILs, characterizing the tumor microenvironment, or investigating immunogenicity, primary cells are essential for the discovery...
In today's presentation I will give an overview to developing NextGen ADCs. We will discuss everything from the beginning stages of development to the varying ADC combination therapies av...
In-vitro epithelial barrier models that are more representative of in-vivo tissues are urgently needed. Here we present extracellular matrix-supported intestinal tubules in a perfused microfl...
Cellular research is optimal when using physiologically-relevant cell phenotypes and genotypes of human origin. This assertion has accelerated the adoption of primary cells, stem cells, and i...
Small size, highly selective nature, flexible chemistry and ease of manufacturing make nucleic acid aptamers attractive for multiple applications in human diagnostics and drug discovery. &nbs...
NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events an...
Isolated hepatocytes or their enzymes comprise the basis of most in vitro DMPK and toxicity assays used to predict human hepatic outcomes. Because hepato-specific functions are typically lost...
Too frequently the investigator will provide “scientific” reasons to justify precluding analgesics from experimental procedures that may involve more than momentary pain, often wi...
Surgery is the first line of treatment for Stage III melanoma. Often adjuvant therapy is administered post-surgery, which can include weeks of radiation, chemotherapy, targeted drug therapy,...
Studies in drug development and on hematological and solid Tumors with a Thymidine Kinase 1 immunoassayThere are many tumor biomarkers but, they mostly reflect tumor mass or past growth,...
NanoMIPs, often called “plastic antibodies”, are made using a proprietary self-assembly process where the template molecule is incubated with monomers, each of which is free in so...
Advanced Cell Diagnostics’ RNAscope products and assay services are utilized widely for tissue-based gene expression analysis in early target validation, preclinical animal efficacy and...